Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer

Urology

Volumn 78, Issue 3, 2011, Pages 626-630

  Oh, William K ^a   Galsky, Matthew D ^a   Stadler, Walter M ^b   Srinivas, Sandy ^c   Chu, Franklin ^d   Bubley, Glenn ^e   Goddard, J ^f   Dunbar, Joi ^f   Ross, Robert W ^f,g  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c STANFORD UNIVERSITY   (United States)

^d San Bernardino Urological   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f Infinity Pharmaceuticals Inc   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; RETASPIMYCIN; TANESPIMYCIN; TESTOSTERONE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLOOD SAMPLING; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPETITIVE INHIBITION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; INSULIN RESISTANCE; KETOACIDOSIS; LIQUID CHROMATOGRAPHY; LIVER FAILURE; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; SOFT TISSUE METASTASIS; STEADY STATE; TESTOSTERONE BLOOD LEVEL; TUMOR VOLUME; VISCERAL METASTASIS; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; BENZOQUINONES; DISEASE PROGRESSION; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 80052330412     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2011.04.041     Document Type: Article

References (28)

1. D.B. Solit, F.F. Zheng, and M. Drobnjak 17-Allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts Clin Cancer Res 8 2002 986 993 (Pubitemid 34517631)
2. D.B. Solit, H.I. Scher, and N. Rosen Hsp90 as a therapeutic target in prostate cancer Semin Oncol 30 2003 709 716 (Pubitemid 37296795)
3. J. Ge, E. Normant, and J.R. Porter Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90 J Med Chem 49 2006 4606 4615 (Pubitemid 44162687)
4. E.I. Heath, D.W. Hillman, and U. Vaishampayan A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer Clin Cancer Res 14 2008 7940 7946
5. D.B. Solit, and G. Chiosis Development and application of Hsp90 inhibitors Drug Discov Today 13 2008 38 43
6. B.E. Hanson, and D.H. Vesole Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent Expert Opin Investig Drugs 18 2009 1375 1383
7. J.R. Sydor, E. Normant, and C.S. Pien Development of 17-allylamino-17- demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90 Proc Natl Acad Sci U S A 103 2006 17408 17413 (Pubitemid 44788982)
8. W. Guo, P. Reigan, and D. Siegel Formation of 17-allylamino- demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H: quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition Cancer Res 65 2005 10006 10015 (Pubitemid 41541482)
9. J.B. Lattouf, R. Srinivasan, and P.A. Pinto Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy Nat Clin Pract Urol 3 2006 590 601 (Pubitemid 44698094)
10. C.R. Williams, R. Tabios, W.M. Linehan, and L. Neckers Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model J Urol 178 2007 1528 1532 (Pubitemid 47376711)
11. Wagner AJ, Morgan JA, Chugh R, et al. Results from phase 1 trial of IPI-504, a novel Hsp90 inhibitor, in tyrosine kinase inhibitor-resistant GIST and other sarcomas. Abstract presented at the American Society of Clinical Oncology 2008 Annual Conference, Chicago, 2008.
12. G.J. Bubley, M. Carducci, and W. Dahut Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 17 1999 3461 3467 (Pubitemid 29517916)
13. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10 (Pubitemid 19099520)
14. J.G. Supko, R.L. Hickman, and M.R. Grever Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent Cancer Chemother Pharmacol 36 1995 305 315
15. U. Banerji, A. O'Donnell, and M. Scurr Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies J Clin Oncol 23 2005 4152 4161 (Pubitemid 46211321)
16. G.S. Nowakowski, A.K. McCollum, and M.M. Ames A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer Clin Cancer Res 12 2006 6087 6093 (Pubitemid 44703773)
17. D.B. Solit, S.P. Ivy, and C. Kopil Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer Clin Cancer Res 13 2007 1775 1782 (Pubitemid 46952945)
18. G. Chiosis, and L. Neckers Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive ACS Chem Biol 1 2006 279 284
19. M.J. Egorin, E.G. Zuhowski, and D.M. Rosen Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1 Cancer Chemother Pharmacol 47 2001 291 302 (Pubitemid 32640768)
20. R.K. Ramanathan, D.L. Trump, and J.L. Eiseman Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers Clin Cancer Res 11 2005 3385 3391 (Pubitemid 40627891)
21. M. Stanbrough, G.J. Bubley, and K. Ross Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res 66 2006 2815 2825
22. B.S. Taylor, N. Schultz, and H. Hieronymus Integrative genomic profiling of human prostate cancer Cancer Cell 18 2010 11 22
23. D.C. Danila, M.J. Morris, and J.S. de Bono Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer J Clin Oncol 28 2010 1496 1501
24. H.I. Scher, T.M. Beer, and C.S. Higano Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 2010 1437 1446
25. N. Craft, Y. Shostak, and M. Carey A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase Nat Med 5 1999 280 285 (Pubitemid 29124362)
26. J. Li, C. Yen, and D. Liaw PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 275 1997 1943 1947 (Pubitemid 27148818)
27. X. Wu, K. Senechal, M.S. Neshat, Y.E. Whang, and C.L. Sawyers The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway Proc Natl Acad Sci U S A 95 1998 15587 15591 (Pubitemid 29018743)
28. S.A. Eccles, A. Massey, and F.I. Raynaud NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis Cancer Res 68 2008 2850